{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T06:27:51Z","timestamp":1788589671441,"version":"build-2803163510"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T00:00:00Z","timestamp":1622678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T00:00:00Z","timestamp":1622678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Key R&D Program of China","award":["2018YFC1311502"],"award-info":[{"award-number":["2018YFC1311502"]}]},{"name":"Gansu Province Health Industry Research Project","award":["GSWSKY2020-08"],"award-info":[{"award-number":["GSWSKY2020-08"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Diabetol"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Aims<\/jats:title>\n                <jats:p>To reduce the burden of type 2 diabetes (T2DM), the disease decision model plays a vital role in supporting decision-making. Currently, there is no comprehensive summary and assessment of the existing decision models for T2DM. The objective of this review is to provide an overview of the characteristics and capabilities of published decision models for T2DM. We also discuss which models are suitable for different study demands.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and methods<\/jats:title>\n                <jats:p>Four databases (PubMed, Web of Science, Embase, and the Cochrane Library) were electronically searched for papers published from inception to August 2020. Search terms were: \u201cDiabetes-Mellitus, Type 2\u201d, \u201ccost-utility\u201d, \u201cquality-of-life\u201d, and \u201cdecision model\u201d. Reference lists of the included studies were manually searched. Two reviewers independently screened the titles and abstracts following the inclusion and exclusion criteria. If there was insufficient information to include or exclude a study, then a full-text version was sought. The extracted information included basic information, study details, population characteristics, basic modeling methodologies, model structure, and data inputs for the included applications, model outcomes, model validation, and uncertainty.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Fourteen unique decision models for T2DM were identified. Markov chains and risk equations were utilized by four and three models, respectively. Three models utilized both. Except for the Archimedes model, all other models (<jats:italic>n<\/jats:italic>\u2009=\u200913) implemented an annual cycle length. The time horizon of most models was flexible. Fourteen models had differences in the division of health states. Ten models emphasized macrovascular and microvascular complications. Six models included adverse events. Majority of the models (<jats:italic>n<\/jats:italic>\u2009=\u200911) were patient-level simulation models. Eleven models simulated annual changes in risk factors (body mass index, glycemia, HbA1c, blood pressure (systolic and\/or diastolic), and lipids (total cholesterol and\/or high-density lipoprotein)). All models reported the main data sources used to develop health states of complications. Most models (<jats:italic>n<\/jats:italic>\u2009=\u200911) could deal with the uncertainty of models, which were described in varying levels of detail in the primary studies. Eleven studies reported that one or more validation checks were performed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The existing decision models for T2DM are heterogeneous in terms of the level of detail in the classification of health states. Thus, more attention should be focused on balancing the desired level of complexity against the required level of transparency in the development of T2DM decision models.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00592-021-01742-6","type":"journal-article","created":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T15:04:53Z","timestamp":1622732693000},"page":"1451-1469","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Decision models in type 2 diabetes mellitus: A systematic review"],"prefix":"10.1007","volume":"58","author":[{"given":"Jiayu","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuedi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4769-4375","authenticated-orcid":false,"given":"Limin","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,3]]},"reference":[{"key":"1742_CR1","unstructured":"International Diabetes Federation (2019) IDF Diabetes Atlas. 9th ed. Brussels: International Diabetes Federation; 2019. Available at http:\/\/www.diabetesatlas.org. Accessed Feb 2020"},{"key":"1742_CR2","doi-asserted-by":"publisher","unstructured":"Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016 (2017). Lancet 390(10100):1260\u20131344. https:\/\/doi.org\/10.1016\/s0140-6736(17)32130-x","DOI":"10.1016\/s0140-6736(17)32130-x"},{"issue":"24","key":"1742_CR3","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1001\/jama.2017.7596","volume":"317","author":"L Wang","year":"2017","unstructured":"Wang L, Gao P, Zhang M et al (2017) Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013. JAMA 317(24):2515\u20132523. https:\/\/doi.org\/10.1001\/jama.2017.7596","journal-title":"JAMA"},{"issue":"12","key":"1742_CR4","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/s2213-8587(14)70144-5","volume":"2","author":"JC Chan","year":"2014","unstructured":"Chan JC, Zhang Y, Ning G (2014) Diabetes in China: a societal solution for a personal challenge. Lancet Diabetes Endocrinol 2(12):969\u2013979. https:\/\/doi.org\/10.1016\/s2213-8587(14)70144-5","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"1742_CR5","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1001\/jama.2013.168118","volume":"310","author":"Y Xu","year":"2013","unstructured":"Xu Y, Wang L, He J et al (2013) Prevalence and control of diabetes in Chinese adults. JAMA 310(9):948\u2013959. https:\/\/doi.org\/10.1001\/jama.2013.168118","journal-title":"JAMA"},{"issue":"3","key":"1742_CR6","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.healthpol.2005.08.008","volume":"77","author":"HA Dakin","year":"2006","unstructured":"Dakin HA, Devlin NJ, Odeyemi IA (2006) \u201cYes\u201d, \u201cNo\u201d or \u201cYes, but\u201d? Multinomial modelling of NICE decision-making. Health Policy 77(3):352\u2013367. https:\/\/doi.org\/10.1016\/j.healthpol.2005.08.008","journal-title":"Health Policy"},{"issue":"6","key":"1742_CR7","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.jval.2012.06.012","volume":"15","author":"JJ Caro","year":"2012","unstructured":"Caro JJ, Briggs AH, Siebert U, Kuntz KM (2012) Modeling good research practices\u2013overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force\u20131. Value Health 15(6):796\u2013803. https:\/\/doi.org\/10.1016\/j.jval.2012.06.012","journal-title":"Value Health"},{"issue":"1","key":"1742_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1046\/j.1524-4733.2003.00234.x","volume":"6","author":"MC Weinstein","year":"2003","unstructured":"Weinstein MC, O\u2019Brien B, Hornberger J et al (2003) Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices-Modeling Studies. Value Health 6(1):9\u201317. https:\/\/doi.org\/10.1046\/j.1524-4733.2003.00234.x","journal-title":"Value Health"},{"issue":"12","key":"1742_CR9","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.2337\/diacare.28.12.2856","volume":"28","author":"H Zhou","year":"2005","unstructured":"Zhou H, Isaman DJM, Messinger S et al (2005) A computer simulation model of diabetes progression, quality of life, and cost. Diabetes Care 28(12):2856\u20132863. https:\/\/doi.org\/10.2337\/diacare.28.12.2856","journal-title":"Diabetes Care"},{"issue":"1","key":"1742_CR10","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1185\/030079906x80350","volume":"22","author":"P McEwan","year":"2006","unstructured":"McEwan P, Peters JR, Bergenheim K, Currie CJ (2006) Evaluation of the costs and outcomes from changes in risk factors in type 2 diabetes using the Cardiff stochastic simulation cost-utility model (DiabForecaster). Curr Med Res Opin 22(1):121\u2013129. https:\/\/doi.org\/10.1185\/030079906x80350","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"1742_CR11","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S1499-2671(07)13007-0","volume":"31","author":"D O'Reilly","year":"2007","unstructured":"O\u2019Reilly D, Hopkins R, Blackhouse G et al (2007) Long-term cost-utility analysis of a multidisciplinary primary care diabetes management program in Ontario. Can J Diabetes 31(3):205\u2013214. https:\/\/doi.org\/10.1016\/S1499-2671(07)13007-0","journal-title":"Can J Diabetes"},{"issue":"19","key":"1742_CR12","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1001\/jama.287.19.2542","volume":"287","author":"TJ Hoerger","year":"2002","unstructured":"Hoerger TJ, Bethke AD, Richter A et al (2002) Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. J Am Med Assoc 287(19):2542\u20132551","journal-title":"J Am Med Assoc"},{"issue":"9","key":"1742_CR13","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.2337\/diacare.27.9.2262","volume":"27","author":"R Kahn","year":"2004","unstructured":"Kahn R (2004) Guidelines for computer modeling of diabetes and its complications. Diabetes Care 27(9):2262\u20132265. https:\/\/doi.org\/10.2337\/diacare.27.9.2262","journal-title":"Diabetes Care"},{"issue":"7","key":"1742_CR14","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1111\/dom.13684","volume":"21","author":"J Leal","year":"2019","unstructured":"Leal J, Morrow LM, Khurshid W, Pagano E, Feenstra T (2019) Decision models of prediabetes populations: a systematic review. Diabetes Obes Metab 21(7):1558\u20131569. https:\/\/doi.org\/10.1111\/dom.13684","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"1742_CR15","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s40273-015-0374-8","volume":"34","author":"M Henriksson","year":"2016","unstructured":"Henriksson M, Jindal R, Sternhufvud C et al (2016) A systematic review of cost-effectiveness models in type 1 diabetes mellitus. Pharmacoeconomics 34(6):569\u2013585. https:\/\/doi.org\/10.1007\/s40273-015-0374-8","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"1742_CR16","doi-asserted-by":"publisher","first-page":"e1003583","DOI":"10.1371\/journal.pmed.1003583","volume":"18","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. PLoS Med 18(3):e1003583. https:\/\/doi.org\/10.1371\/journal.pmed.1003583","journal-title":"PLoS Med"},{"issue":"4","key":"1742_CR17","doi-asserted-by":"publisher","first-page":"355","DOI":"10.2165\/00019053-200624040-00006","volume":"24","author":"Z Philips","year":"2006","unstructured":"Philips Z, Bojke L, Sculpher M, Claxton K, Golder S (2006) Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment. Pharmacoeconomics 24(4):355\u2013371. https:\/\/doi.org\/10.2165\/00019053-200624040-00006","journal-title":"Pharmacoeconomics"},{"key":"1742_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/pharmacy7010030","author":"D Wright","year":"2019","unstructured":"Wright D, Little R, Turner D, Thornley T (2019) Diabetes screening through community pharmacies in England: A cost-effectiveness study. Pharm (Basel). https:\/\/doi.org\/10.3390\/pharmacy7010030","journal-title":"Pharm (Basel)"},{"issue":"11","key":"1742_CR19","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.2337\/diacare.26.11.3093","volume":"26","author":"DM Eddy","year":"2003","unstructured":"Eddy DM, Schlessinger L (2003) Archimedes: a trial-validated model of diabetes. Diabetes Care 26(11):3093\u20133101. https:\/\/doi.org\/10.2337\/diacare.26.11.3093","journal-title":"Diabetes Care"},{"issue":"5","key":"1742_CR20","doi-asserted-by":"publisher","first-page":"725","DOI":"10.2337\/diacare.20.5.725","volume":"20","author":"RC Eastman","year":"1997","unstructured":"Eastman RC, Javitt JC, Herman WH et al (1997) Model of complications of NIDDM I Model construction and assumptions. Diabetes Care 20(5):725\u2013734","journal-title":"Diabetes Care"},{"issue":"10","key":"1742_CR21","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1007\/s00125-004-1527-z","volume":"47","author":"PM Clarke","year":"2004","unstructured":"Clarke PM, Gray AM, Briggs A et al (2004) A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom prospective diabetes study (UKPDS) outcomes model (UKPDS No. 68). Diabetologia 47(10):1747\u20131759. https:\/\/doi.org\/10.1007\/s00125-004-1527-z","journal-title":"Diabetologia"},{"key":"1742_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c4093","author":"M Gillett","year":"2010","unstructured":"Gillett M, Dallosso HM, Dixon S et al (2010) Delivering the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: Cost effectiveness analysis. BMJ. https:\/\/doi.org\/10.1136\/bmj.c4093","journal-title":"BMJ"},{"key":"1742_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0110235","author":"A Lundqvist","year":"2014","unstructured":"Lundqvist A, Carlsson KS, Johansen P, Andersson E, Willis M (2014) Validation of the IHE cohort model of type 2 diabetes and the impact of choice of macrovascular risk equations. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0110235","journal-title":"PLoS ONE"},{"issue":"8","key":"1742_CR24","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.3111\/13696998.2013.809352","volume":"16","author":"M Willis","year":"2013","unstructured":"Willis M, Asseburg C, He J (2013) Validation of economic and health outcomes simulation model of type 2 diabetes mellitus (ECHO-T2DM). J Med Econ 16(8):1007\u20131021. https:\/\/doi.org\/10.3111\/13696998.2013.809352","journal-title":"J Med Econ"},{"key":"1742_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s41669-019-0156-x","author":"ZT Su","year":"2019","unstructured":"Su ZT, Bartelt-Hofer J, Brown S et al (2019) The use of computer simulation modeling to estimate complications in patients with type 2 diabetes mellitus: comparative validation of the cornerstone diabetes simulation model. Pharmacoecon Open. https:\/\/doi.org\/10.1007\/s41669-019-0156-x","journal-title":"Pharmacoecon Open"},{"key":"1742_CR26","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2018-0001","author":"B Wu","year":"2018","unstructured":"Wu B, Ma J, Zhang S, Zhou L, Wu H (2018) Development and validation of a health policy model of type 2 diabetes in Chinese setting. J Comparative Effect Res. https:\/\/doi.org\/10.2217\/cer-2018-0001","journal-title":"J Comparative Effect Res"},{"issue":"Suppl 1","key":"1742_CR27","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1185\/030079904x1980","volume":"20","author":"AJ Palmer","year":"2004","unstructured":"Palmer AJ, Roze S, Valentine WJ et al (2004) The CORE Diabetes model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 20(Suppl 1):S5-26. https:\/\/doi.org\/10.1185\/030079904x1980","journal-title":"Curr Med Res Opin"},{"issue":"9","key":"1742_CR28","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1007\/s00125-013-2940-y","volume":"56","author":"AJ Hayes","year":"2013","unstructured":"Hayes AJ, Leal J, Gray AM, Holman RR, Clarke PM (2013) UKPDS Outcomes Model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom prospective diabetes study: UKPDS 82. Diabetologia 56(9):1925\u20131933. https:\/\/doi.org\/10.1007\/s00125-013-2940-y","journal-title":"Diabetologia"},{"issue":"1","key":"1742_CR29","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40273-013-0117-7","volume":"32","author":"CV Asche","year":"2014","unstructured":"Asche CV, Hippler SE, Eurich DT (2014) Review of models used in economic analyses of new oral treatments for type 2 diabetes mellitus. Pharmacoeconomics 32(1):15\u201327. https:\/\/doi.org\/10.1007\/s40273-013-0117-7","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"1742_CR30","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1586\/erp.11.68","volume":"11","author":"C Becker","year":"2011","unstructured":"Becker C, Langer A, Leidl R (2011) The quality of three decision-analytic diabetes models: a systematic health economic assessment. Expert Rev Pharmacoecon Outcomes Res 11(6):751\u2013762. https:\/\/doi.org\/10.1586\/erp.11.68","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"9","key":"1742_CR31","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1185\/03007995.2010.494451","volume":"26","author":"Y Yi","year":"2010","unstructured":"Yi Y, Philips Z, Bergman G, Burslem K (2010) Economic models in type 2 diabetes. Curr Med Res Opin 26(9):2105\u20132118. https:\/\/doi.org\/10.1185\/03007995.2010.494451","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"1742_CR32","doi-asserted-by":"publisher","first-page":"255","DOI":"10.2165\/11531590-000000000-00000","volume":"28","author":"JE Tarride","year":"2010","unstructured":"Tarride JE, Hopkins R, Blackhouse G et al (2010) A review of methods used in long-term cost-effectiveness models of diabetes mellitus treatment. Pharmacoeconomics 28(4):255\u2013277. https:\/\/doi.org\/10.2165\/11531590-000000000-00000","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"1742_CR33","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/0002-8703(86)90155-9","volume":"111","author":"DJ Lerner","year":"1986","unstructured":"Lerner DJ, Kannel WB (1986) Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am Heart J 111(2):383\u2013390. https:\/\/doi.org\/10.1016\/0002-8703(86)90155-9","journal-title":"Am Heart J"},{"issue":"10","key":"1742_CR34","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.2337\/diacare.16.10.1325","volume":"16","author":"R Klein","year":"1993","unstructured":"Klein R, Klein BE, Moss SE (1993) Prevalence of microalbuminuria in older-onset diabetes. Diabetes Care 16(10):1325\u20131330. https:\/\/doi.org\/10.2337\/diacare.16.10.1325","journal-title":"Diabetes Care"},{"issue":"4","key":"1742_CR35","doi-asserted-by":"publisher","first-page":"405","DOI":"10.2337\/diab.37.4.405","volume":"37","author":"DJ Ballard","year":"1988","unstructured":"Ballard DJ, Humphrey LL, Melton LJ 3rd et al (1988) Epidemiology of persistent proteinuria in type II diabetes mellitus Population-based study in Rochester Minnesota. Diabetes 37(4):405\u2013412. https:\/\/doi.org\/10.2337\/diab.37.4.405","journal-title":"Diabetes"},{"issue":"8","key":"1742_CR36","doi-asserted-by":"publisher","first-page":"909","DOI":"10.2337\/diacare.17.8.909","volume":"17","author":"JC Javitt","year":"1994","unstructured":"Javitt JC, Aiello LP, Chiang Y et al (1994) Preventive eye care in people with diabetes is cost-saving to the federal government. Implications for health-care reform. Diabetes Care 17(8):909\u2013917. https:\/\/doi.org\/10.2337\/diacare.17.8.909","journal-title":"Diabetes Care"},{"issue":"2","key":"1742_CR37","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1001\/archopht.1989.01070010250031","volume":"107","author":"R Klein","year":"1989","unstructured":"Klein R, Klein BE, Moss SE, Davis MD, DeMets DL (1989) The Wisconsin Epidemiologic Study of Diabetic Retinopathy. X. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is 30 years or more. Arch Ophthalmol 107(2):244\u2013249. https:\/\/doi.org\/10.1001\/archopht.1989.01070010250031","journal-title":"Arch Ophthalmol"},{"issue":"4","key":"1742_CR38","doi-asserted-by":"publisher","first-page":"530","DOI":"10.2337\/diacare.21.4.530","volume":"21","author":"JY Park","year":"1998","unstructured":"Park JY, Kim HK, Chung YE, Kim SW, Hong SK, Lee KU (1998) Incidence and determinants of microalbuminuria in Koreans with type 2 diabetes. Diabetes Care 21(4):530\u2013534. https:\/\/doi.org\/10.2337\/diacare.21.4.530","journal-title":"Diabetes Care"},{"issue":"4","key":"1742_CR39","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1212\/wnl.43.4.817","volume":"43","author":"PJ Dyck","year":"1993","unstructured":"Dyck PJ, Kratz KM, Karnes JL et al (1993) The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology 43(4):817\u2013824. https:\/\/doi.org\/10.1212\/wnl.43.4.817","journal-title":"Neurology"},{"issue":"11","key":"1742_CR40","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.2105\/ajph.77.11.1417","volume":"77","author":"MC Weinstein","year":"1987","unstructured":"Weinstein MC, Coxson PG, Williams LW et al (1987) Forecasting coronary heart disease incidence, mortality, and cost: the Coronary Heart Disease Policy Model. Am J Public Health 77(11):1417\u20131426. https:\/\/doi.org\/10.2105\/ajph.77.11.1417","journal-title":"Am J Public Health"},{"issue":"1 Pt 2","key":"1742_CR41","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/0002-8703(91)90861-b","volume":"121","author":"KM Anderson","year":"1991","unstructured":"Anderson KM, Odell PM, Wilson PW, Kannel WB (1991) Cardiovascular disease risk profiles. Am Heart J 121(1 Pt 2):293\u2013298. https:\/\/doi.org\/10.1016\/0002-8703(91)90861-b","journal-title":"Am Heart J"},{"issue":"7","key":"1742_CR42","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1001\/jama.1997.03540310033031","volume":"277","author":"MG Hunink","year":"1997","unstructured":"Hunink MG, Goldman L, Tosteson AN et al (1997) The recent decline in mortality from coronary heart disease, 1980\u20131990. The effect of secular trends in risk factors and treatment. JAMA 277(7):535\u2013542","journal-title":"JAMA"},{"issue":"5","key":"1742_CR43","doi-asserted-by":"publisher","first-page":"735","DOI":"10.2337\/diacare.20.5.735","volume":"20","author":"RC Eastman","year":"1997","unstructured":"Eastman RC, Javitt JC, Herman WH et al (1997) Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care 20(5):735\u2013744","journal-title":"Diabetes Care"},{"issue":"2 Pt 1","key":"1742_CR44","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1067\/mhj.2000.96469","volume":"139","author":"RB D'Agostino","year":"2000","unstructured":"D\u2019Agostino RB, Russell MW, Huse DM et al (2000) Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J 139(2 Pt 1):272\u2013281. https:\/\/doi.org\/10.1067\/mhj.2000.96469","journal-title":"Am Heart J"},{"issue":"5","key":"1742_CR45","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1159\/000177131","volume":"87","author":"J Herlitz","year":"1996","unstructured":"Herlitz J, B\u00e5ng A, Karlson BW (1996) Mortality, place and mode of death and reinfarction during a period of 5 years after acute myocardial infarction in diabetic and non-diabetic patients. Cardiology 87(5):423\u2013428. https:\/\/doi.org\/10.1159\/000177131","journal-title":"Cardiology"},{"issue":"9","key":"1742_CR46","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1053\/euhj.1999.1859","volume":"21","author":"B Almbrand","year":"2000","unstructured":"Almbrand B, Johannesson M, Sj\u00f6strand B, Malmberg K, Ryd\u00e9n L (2000) Cost-effectiveness of intense insulin treatment after acute myocardial infarction in patients with diabetes mellitus; results from the DIGAMI study. Eur Heart J 21(9):733\u2013739. https:\/\/doi.org\/10.1053\/euhj.1999.1859","journal-title":"Eur Heart J"},{"issue":"23","key":"1742_CR47","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1056\/nejm199912023412303","volume":"341","author":"RA Wolfe","year":"1999","unstructured":"Wolfe RA, Ashby VB, Milford EL et al (1999) Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 341(23):1725\u20131730. https:\/\/doi.org\/10.1056\/nejm199912023412303","journal-title":"N Engl J Med"},{"issue":"2","key":"1742_CR48","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1001\/archopht.1989.01070010243030","volume":"107","author":"R Klein","year":"1989","unstructured":"Klein R, Klein BE, Moss SE, Davis MD, DeMets DL (1989) The wisconsin epidemiologic study of diabetic retinopathy. IX. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 107(2):237\u2013243. https:\/\/doi.org\/10.1001\/archopht.1989.01070010243030","journal-title":"Arch Ophthalmol"},{"issue":"9095","key":"1742_CR49","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/s0140-6736(97)06209-0","volume":"351","author":"N Chaturvedi","year":"1998","unstructured":"Chaturvedi N, Sjolie AK, Stephenson JM et al (1998) Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 351(9095):28\u201331. https:\/\/doi.org\/10.1016\/s0140-6736(97)06209-0","journal-title":"Lancet"},{"issue":"2","key":"1742_CR50","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s001250051594","volume":"44","author":"IM Stratton","year":"2001","unstructured":"Stratton IM, Kohner EM, Aldington SJ et al (2001) UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. Diabetologia 44(2):156\u2013163. https:\/\/doi.org\/10.1007\/s001250051594","journal-title":"Diabetologia"},{"issue":"2","key":"1742_CR51","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1056\/nejm199507133330203","volume":"333","author":"J Partanen","year":"1995","unstructured":"Partanen J, Niskanen L, Lehtinen J et al (1995) Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 333(2):89\u201394. https:\/\/doi.org\/10.1056\/nejm199507133330203","journal-title":"N Engl J Med"},{"key":"1742_CR52","doi-asserted-by":"publisher","unstructured":"The effect of intensive diabetes therapy on the development and progression of neuropathy The Diabetes Control and Complications Trial Research Group (1995). Ann Intern Med 122(8):561\u2013568. https:\/\/doi.org\/10.7326\/0003-4819-122-8-199504150-00001","DOI":"10.7326\/0003-4819-122-8-199504150-00001"},{"issue":"1","key":"1742_CR53","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1212\/wnl.50.1.208","volume":"50","author":"GW Petty","year":"1998","unstructured":"Petty GW, Brown RD Jr, Whisnant JP et al (1998) Survival and recurrence after first cerebral infarction: a population-based study in Rochester, Minnesota, 1975 through 1989. Neurology 50(1):208\u2013216. https:\/\/doi.org\/10.1212\/wnl.50.1.208","journal-title":"Neurology"},{"issue":"7","key":"1742_CR54","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1111\/j.1464-5491.1994.tb00332.x","volume":"11","author":"JM Sprafka","year":"1994","unstructured":"Sprafka JM, Virnig BA, Shahar E, McGovern PG (1994) Trends in diabetes prevalence among stroke patients and the effect of diabetes on stroke survival: the Minnesota Heart Survey. Diabet Med 11(7):678\u2013684. https:\/\/doi.org\/10.1111\/j.1464-5491.1994.tb00332.x","journal-title":"Diabet Med"},{"issue":"11","key":"1742_CR55","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1007\/s001250100013","volume":"44","author":"G Ragnarson Tennvall","year":"2001","unstructured":"Ragnarson Tennvall G, Apelqvist J (2001) Prevention of diabetes-related foot ulcers and amputations: a cost-utility analysis based on Markov model simulations. Diabetologia 44(11):2077\u20132087. https:\/\/doi.org\/10.1007\/s001250100013","journal-title":"Diabetologia"},{"issue":"3","key":"1742_CR56","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1001\/archinte.159.3.281","volume":"159","author":"H Ben-Ami","year":"1999","unstructured":"Ben-Ami H, Nagachandran P, Mendelson A, Edoute Y (1999) Drug-induced hypoglycemic coma in 102 diabetic patients. Arch Intern Med 159(3):281\u2013284. https:\/\/doi.org\/10.1001\/archinte.159.3.281","journal-title":"Arch Intern Med"},{"issue":"2","key":"1742_CR57","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/bf03324137","volume":"5","author":"M Stepka","year":"1993","unstructured":"Stepka M, Rogala H, Czyzyk A (1993) Hypoglycemia: a major problem in the management of diabetes in the elderly. Aging (Milano) 5(2):117\u2013121. https:\/\/doi.org\/10.1007\/bf03324137","journal-title":"Aging (Milano)"},{"key":"1742_CR58","doi-asserted-by":"crossref","unstructured":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group (1998). Lancet 352(9131):837\u2013853","DOI":"10.1016\/S0140-6736(98)07019-6"},{"issue":"9","key":"1742_CR59","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1161\/01.cir.102.9.1014","volume":"102","author":"K Malmberg","year":"2000","unstructured":"Malmberg K, Yusuf S, Gerstein HC et al (2000) Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation 102(9):1014\u20131019. https:\/\/doi.org\/10.1161\/01.cir.102.9.1014","journal-title":"Circulation"},{"issue":"8","key":"1742_CR60","doi-asserted-by":"publisher","first-page":"787","DOI":"10.2337\/diab.34.8.787","volume":"34","author":"G Ulvenstam","year":"1985","unstructured":"Ulvenstam G, Aberg A, Bergstrand R et al (1985) Long-term prognosis after myocardial infarction in men with diabetes. Diabetes 34(8):787\u2013792. https:\/\/doi.org\/10.2337\/diab.34.8.787","journal-title":"Diabetes"},{"issue":"2","key":"1742_CR61","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1007\/s001250050032","volume":"43","author":"H L\u00f6wel","year":"2000","unstructured":"L\u00f6wel H, Koenig W, Engel S, H\u00f6rmann A, Keil U (2000) The impact of diabetes mellitus on survival after myocardial infarction: can it be modified by drug treatment? Results of a population-based myocardial infarction register follow-up study. Diabetologia 43(2):218\u2013226. https:\/\/doi.org\/10.1007\/s001250050032","journal-title":"Diabetologia"},{"issue":"6","key":"1742_CR62","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1042\/CS20000335","volume":"101","author":"RJ Stevens","year":"2001","unstructured":"Stevens RJ, Kothari V, Adler AI, Stratton IM (2001) The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci (Lond) 101(6):671\u2013679","journal-title":"Clin Sci (Lond)"},{"issue":"7083","key":"1742_CR63","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1136\/bmj.314.7083.783","volume":"314","author":"MA Gall","year":"1997","unstructured":"Gall MA, Hougaard P, Borch-Johnsen K, Parving HH (1997) Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study. BMJ 314(7083):783\u2013788. https:\/\/doi.org\/10.1136\/bmj.314.7083.783","journal-title":"BMJ"},{"issue":"8","key":"1742_CR64","doi-asserted-by":"publisher","first-page":"577","DOI":"10.7326\/0003-4819-118-8-199304150-00001","volume":"118","author":"M Ravid","year":"1993","unstructured":"Ravid M, Savin H, Jutrin I et al (1993) Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 118(8):577\u2013581. https:\/\/doi.org\/10.7326\/0003-4819-118-8-199304150-00001","journal-title":"Ann Intern Med"},{"issue":"9","key":"1742_CR65","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1001\/archopht.1994.01090210105023","volume":"112","author":"R Klein","year":"1994","unstructured":"Klein R, Klein BE, Moss SE, Cruickshanks KJ (1994) The Wisconsin Epidemiologic Study of diabetic retinopathy XIV Ten-year incidence and progression of diabetic retinopathy. Arch Ophthalmol 112(9):1217\u20131228. https:\/\/doi.org\/10.1001\/archopht.1994.01090210105023","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"1742_CR66","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/s0161-6420(95)31052-4","volume":"102","author":"R Klein","year":"1995","unstructured":"Klein R, Klein BE, Moss SE, Cruickshanks KJ (1995) The wisconsin epidemiologic study of diabetic retinopathy. XV. The long-term incidence of macular edema. Ophthalmology 102(1):7\u201316. https:\/\/doi.org\/10.1016\/s0161-6420(95)31052-4","journal-title":"Ophthalmology"},{"issue":"10","key":"1742_CR67","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1016\/s0161-6420(88)32991-x","volume":"95","author":"SE Moss","year":"1988","unstructured":"Moss SE, Klein R, Klein BE (1988) The incidence of vision loss in a diabetic population. Ophthalmology 95(10):1340\u20131348. https:\/\/doi.org\/10.1016\/s0161-6420(88)32991-x","journal-title":"Ophthalmology"},{"issue":"6","key":"1742_CR68","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/s0161-6420(94)31217-6","volume":"101","author":"SE Moss","year":"1994","unstructured":"Moss SE, Klein R, Klein BE (1994) Ten-year incidence of visual loss in a diabetic population. Ophthalmology 101(6):1061\u20131070. https:\/\/doi.org\/10.1016\/s0161-6420(94)31217-6","journal-title":"Ophthalmology"},{"issue":"3","key":"1742_CR69","doi-asserted-by":"publisher","first-page":"322","DOI":"10.2337\/diacare.20.3.322","volume":"20","author":"ML Sands","year":"1997","unstructured":"Sands ML, Shetterly SM, Franklin GM, Hamman RF (1997) Incidence of distal symmetric (sensory) neuropathy in NIDDM. The San Luis valley diabetes study. Diabetes Care 20(3):322\u2013329. https:\/\/doi.org\/10.2337\/diacare.20.3.322","journal-title":"Diabetes Care"},{"issue":"7","key":"1742_CR70","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.2337\/diacare.22.7.1029","volume":"22","author":"AI Adler","year":"1999","unstructured":"Adler AI, Boyko EJ, Ahroni JH, Smith DG (1999) Lower-extremity amputation in diabetes. The independent effects of peripheral vascular disease, sensory neuropathy, and foot ulcers. Diabetes Care 22(7):1029\u20131035. https:\/\/doi.org\/10.2337\/diacare.22.7.1029","journal-title":"Diabetes Care"},{"issue":"2","key":"1742_CR71","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1161\/01.str.22.2.155","volume":"22","author":"DB Hier","year":"1991","unstructured":"Hier DB, Foulkes MA, Swiontoniowski M et al (1991) Stroke recurrence within 2 years after ischemic infarction. Stroke 22(2):155\u2013161. https:\/\/doi.org\/10.1161\/01.str.22.2.155","journal-title":"Stroke"},{"issue":"4","key":"1742_CR72","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1212\/wnl.44.4.626","volume":"44","author":"RL Sacco","year":"1994","unstructured":"Sacco RL, Shi T, Zamanillo MC, Kargman DE (1994) Predictors of mortality and recurrence after hospitalized cerebral infarction in an urban community: the Northern Manhattan Stroke Study. Neurology 44(4):626\u2013634. https:\/\/doi.org\/10.1212\/wnl.44.4.626","journal-title":"Neurology"},{"issue":"7","key":"1742_CR73","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1161\/01.str.0000020091.07144.c7","volume":"33","author":"V Kothari","year":"2002","unstructured":"Kothari V, Stevens RJ, Adler AI et al (2002) UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK prospective diabetes study risk engine. Stroke 33(7):1776\u20131781. https:\/\/doi.org\/10.1161\/01.str.0000020091.07144.c7","journal-title":"Stroke"},{"issue":"1","key":"1742_CR74","doi-asserted-by":"publisher","first-page":"42","DOI":"10.2337\/diacare.21.1.42","volume":"21","author":"CJ Currie","year":"1998","unstructured":"Currie CJ, Morgan CL, Peters JR (1998) The epidemiology and cost of inpatient care for peripheral vascular disease, infection, neuropathy, and ulceration in diabetes. Diabetes Care 21(1):42\u201348. https:\/\/doi.org\/10.2337\/diacare.21.1.42","journal-title":"Diabetes Care"},{"issue":"6","key":"1742_CR75","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1046\/j.1464-5491.2003.00972.x","volume":"20","author":"P Clarke","year":"2003","unstructured":"Clarke P, Gray A, Legood R, Briggs A, Holman R (2003) The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65). Diabet Med 20(6):442\u2013450. https:\/\/doi.org\/10.1046\/j.1464-5491.2003.00972.x","journal-title":"Diabet Med"},{"key":"1742_CR76","doi-asserted-by":"publisher","unstructured":"Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group (1995). Kidney Int 47(6):1703\u20131720. https:\/\/doi.org\/10.1038\/ki.1995.236","DOI":"10.1038\/ki.1995.236"},{"issue":"12","key":"1742_CR77","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1007\/s001250100023","volume":"44","author":"A Bagust","year":"2001","unstructured":"Bagust A, Hopkinson PK, Maier W, Currie CJ (2001) An economic model of the long-term health care burden of type II diabetes. Diabetologia 44(12):2140\u20132155. https:\/\/doi.org\/10.1007\/s001250100023","journal-title":"Diabetologia"},{"issue":"5","key":"1742_CR78","doi-asserted-by":"publisher","first-page":"e62650","DOI":"10.1371\/journal.pone.0062650","volume":"8","author":"A Ahmad Kiadaliri","year":"2013","unstructured":"Ahmad Kiadaliri A, Gerdtham UG, Nilsson P et al (2013) Towards renewed health economic simulation of type 2 diabetes: risk equations for first and second cardiovascular events from Swedish register data. PLoS ONE 8(5):e62650. https:\/\/doi.org\/10.1371\/journal.pone.0062650","journal-title":"PLoS ONE"},{"issue":"Suppl 3","key":"1742_CR79","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1016\/s0168-8227(00)00215-1","volume":"50","author":"JB Brown","year":"2000","unstructured":"Brown JB, Russell A, Chan W, Pedula K, Aickin M (2000) The global diabetes model: user friendly version 3.0. Diabetes Res Clin Pract 50(Suppl 3):S15-46. https:\/\/doi.org\/10.1016\/s0168-8227(00)00215-1","journal-title":"Diabetes Res Clin Pract"},{"issue":"9","key":"1742_CR80","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1056\/NEJMoa1006524","volume":"364","author":"HC Gerstein","year":"2011","unstructured":"Gerstein HC, Miller ME, Genuth S et al (2011) Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 364(9):818\u2013828. https:\/\/doi.org\/10.1056\/NEJMoa1006524","journal-title":"N Engl J Med"},{"issue":"2","key":"1742_CR81","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1056\/NEJMoa1212914","volume":"369","author":"RR Wing","year":"2013","unstructured":"Wing RR, Bolin P, Brancati FL et al (2013) Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 369(2):145\u2013154. https:\/\/doi.org\/10.1056\/NEJMoa1212914","journal-title":"N Engl J Med"},{"issue":"9833","key":"1742_CR82","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1016\/s0140-6736(12)60525-x","volume":"379","author":"L Perreault","year":"2012","unstructured":"Perreault L, Pan Q, Mather KJ et al (2012) Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the diabetes prevention program outcomes study. Lancet 379(9833):2243\u20132251. https:\/\/doi.org\/10.1016\/s0140-6736(12)60525-x","journal-title":"Lancet"},{"issue":"24","key":"1742_CR83","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","volume":"358","author":"A Patel","year":"2008","unstructured":"Patel A, MacMahon S, Chalmers J et al (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358(24):2560\u20132572. https:\/\/doi.org\/10.1056\/NEJMoa0802987","journal-title":"N Engl J Med"},{"issue":"7","key":"1742_CR84","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.2337\/dc05-2150","volume":"29","author":"PM Clarke","year":"2006","unstructured":"Clarke PM, Simon J, Cull CA, Holman RR (2006) Assessing the impact of visual acuity on quality of life in individuals with type 2 diabetes using the short form-36. Diabetes Care 29(7):1506\u20131511. https:\/\/doi.org\/10.2337\/dc05-2150","journal-title":"Diabetes Care"},{"issue":"2","key":"1742_CR85","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s40273-014-0225-z","volume":"33","author":"P McEwan","year":"2015","unstructured":"McEwan P, Bennett H, Ward T, Bergenheim K (2015) Refitting of the UKPDS 68 risk equations to contemporary routine clinical practice data in the UK. Pharmacoeconomics 33(2):149\u2013161. https:\/\/doi.org\/10.1007\/s40273-014-0225-z","journal-title":"Pharmacoeconomics"},{"key":"1742_CR86","doi-asserted-by":"publisher","unstructured":"Diabetes Control and Complications Trial Research Group (1995) The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial. Arch Ophthalmol 113(1):36\u201351. https:\/\/doi.org\/10.1001\/archopht.1995.01100010038019","DOI":"10.1001\/archopht.1995.01100010038019"}],"container-title":["Acta Diabetologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-021-01742-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00592-021-01742-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-021-01742-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T15:49:54Z","timestamp":1633967394000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00592-021-01742-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,3]]},"references-count":86,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["1742"],"URL":"https:\/\/doi.org\/10.1007\/s00592-021-01742-6","relation":{},"ISSN":["0940-5429","1432-5233"],"issn-type":[{"value":"0940-5429","type":"print"},{"value":"1432-5233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,3]]},"assertion":[{"value":"27 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by the any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights disclosure"}},{"value":"No identifying information from individual patients was retrieved or published at any stage by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}